Released Nov 10, 2022, before the open
10-Q filed Nov 10, 2022, 41 days after period end · 0001785530-22-000038
Q3 2022 · 10-Q
Revenue—
Net Income-$11.94M-$11.94M N/M vs Q3 2021N/M vs Q2 2022
EPS Diluted-$0.40-$0.40 N/M vs Q3 2021N/M vs Q2 2022
Operating Income-$12,539,000N/M
Operating Cash Flowderived-$14,472,000N/M
Free Cash Flowderived-$16,426,000N/M
What the release said
The release
Same quarter
| Metric | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|
| Net Income | -$11.94M | -$13.76M | -$6.07M |
| EPS Diluted | -$0.40 | -$0.51 | -$6.61 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR